PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THIRD QUARTER ENDED DECEMBER 31, 2021
February 03 2022 - 2:38PM
PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging
biomedical device company focused on the commercialization of
innovative medical therapeutics for animals, will report financial
results on Thursday, February 10, 2022 after market close. The
company will host a conference call to discuss these results at
4:00 p.m. CT (5:00 p.m. ET) on the same day.
A live webcast of the conference call and
related earnings release materials can be accessed on PetVivo’s
Investor Relations website at
https://audience.mysequire.com/webinar-view?webinar_id=c0d62920-a22f-4c6e-bd3f-c9a2d44daecb.
A replay of the webcast will be available through the same link
following the conference call. Participants can also access the
call using the dial-in details below.
Date: Thursday, February 10, 2022 Time: 4:00 p.m CT (5:00 pm
ET)Dial-in number: +1 (669) 900-6833 Conference ID:
99870885526Passcode: 297536
Please call the conference telephone number 5-10
minutes prior to the start time. An operator will register your
name and number.
Disclosure Information
PetVivo uses and intends to continue to use its
Investor Relations website as a means of disclosing material
nonpublic information and for complying with its disclosure
obligations under Regulation FD. Accordingly, investors should
monitor the company’s Investor Relations website, in addition to
following the company’s press releases, SEC filings, public
conference calls, presentations and webcasts.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV and PETVW)
is an emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for animals. The Company's
strategy is to leverage human therapies for the treatment of dogs
and horses in a capital and time efficient way. A key component of
this strategy is the accelerated timeline to revenues for
veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of twenty-one
patents protects the Company's biomaterials, products, production
processes and methods of use. The Company’s lead product SPRYNG™, a
veterinarian-administered, intraarticular injection for the
treatment of osteoarthritis in dogs and horses, was made available
for commercial sale in September, 2021.
CONTACT:
John Lai, CEOPetVivo Holdings, Inc.Email: info1@petvivo.com(952)
405-6216
PetVivo (NASDAQ:PETVW)
Historical Stock Chart
From Aug 2024 to Sep 2024
PetVivo (NASDAQ:PETVW)
Historical Stock Chart
From Sep 2023 to Sep 2024